Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing

Waldenstrom's Macroglobulinemia Clinical Trial

Official title:

Phase II Study of Ibrutinib in Patients With Symptomatic, Previously Untreated Waldenstrom's Macroglobulinemia, and Impact on Tumor Genomic Evolution Using Whole Genome Sequencing

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02604511
• Other study ID #: 15-359
• Status: Completed
• Phase: Phase 2
• Start date: January 2016
• Est. completion date: November 1, 2022

Study information

• Verified date: December 2022
• Source: Dana-Farber Cancer Institute
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This research study is studying a drug called ibrutinib as a possible treatment for untreated Waldenstrom's Macroglobulinemia (WM).

Description:

This research study is a Phase II clinical trial. Phase II clinical trials test the safety and effectiveness of an investigational intervention to learn whether the intervention works in treating a specific disease. "Investigational" means that the intervention is being studied.

The FDA (the U.S. Food and Drug Administration) has approved ibrutinib as a form of treatment for the patient specific disease.

Ibrutinib has been under investigation in research studies in participants with recurrent B-cell lymphoma, chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), mantle cell lymphoma (MCL), diffuse large B-cell lymphoma (DLBCL), and prolymphocytic leukemia, and WM. In a study of ibrutinib in relapsed/refractory WM patients, response rates were high and the treatment was well tolerated.

The prior studies suggest that ibrutinib may be a useful treatment strategy for untreated WM patients. This study will test the safety and efficacy of ibrutinib as an option for untreated WM patients. The study will also conduct genomic sequencing of malignant WM cells before the start of treatment, and 6, 12, 24, 36 and 48 months afterwards. Genomic sequencing is the analysis of the entire DNA structure from tumor and normal cells. The purpose of this sequencing is to study which genetic changes effect how ibrutinib works. The results of these studies could also help in better understanding the course of WM disease, and be applicable to the development of other effective drug treatments.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 31
• Est. completion date: November 1, 2022
• Est. primary completion date: November 1, 2022
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Clinicopathological diagnosis of Waldenstrom's Macroglobulinemia and meeting criteria for treatment using consensus panel criteria from the Second International Workshop on Waldenstrom's macroglobulinemia (Kyle et al, 2003).

• Measurable disease, defined as presence of serum immunoglobulin M (IgM) with a minimum IgM level of = 2 times the upper limit of normal is required.

• Age = 18 years.

• Eastern Cooperative Oncology Group (ECOG) performance status =2 (see Appendix A.).

• Participants must have normal organ and marrow function as defined below:

• Absolute neutrophil count = 1,000/µL

• Platelets = 50,000/µL

• Hemoglobin = 8 g/dL

• Total bilirubin = 2.0. mg/dL or < 2.5 mg/dL if attributable to hepatic infiltration by neoplastic disease or Gilbert's syndrome.

• Aspartate aminotransferase (AST or SGOT) and Alanine aminotransferase (ALT or SGPT) = 2.5 X institutional upper limit of normal

• Estimated Creatinine Clearance =30ml/min

• Not on any active therapy for other malignancies with the exception of topical therapies for basal cell or squamous cell cancers of the skin.

• Females of childbearing potential (FCBP) must agree to use two reliable forms of contraception simultaneously or have or will have complete abstinence from heterosexual intercourse during the following time periods related to this study: 1) while participating in the study; and 2) for at least 28 days after discontinuation from the study. Men must agree to use a latex condom during sexual contact with a FCBP even if they have had a successful vasectomy. FCBP must be referred to a qualified provider of contraceptive methods if needed.

• Able to adhere to the study visit schedule and other protocol requirements.

• Ability to understand and the willingness to sign a written informed consent document.

• Both men and women of all races and ethnic groups are eligible for this trial.

Exclusion Criteria:

• Prior systemic therapy for WM

• Any serious medical condition, laboratory abnormality, uncontrolled intercurrent illness, or psychiatric illness/social condition that would prevent the participant from signing the informed consent form.

• Concurrent use of any other anti-cancer treatments or any other investigational agents.

• Concomitant use of warfarin or other Vitamin K antagonists.

• Concomitant treatment with strong CYP3A4/5 inhibitor.

• Any condition, including the presence of laboratory abnormalities, which places the participant at unacceptable risk if he/she were to participate in the study or confounds the ability to interpret data from the study.

• Any life-threatening illness, medical condition, or organ system dysfunction which, in the investigator's opinion could interfere with the absorption or metabolism of ibrutinib.

• Known Central nervous system (CNS) lymphoma.

• Concomitant use of medication known to cause QT prolongation.

• Currently active, clinically significant cardiovascular disease such as uncontrolled or symptomatic arrhythmias, Class 3 or 4 congestive heart failure as defined by the New York Heart Association Functional Classification, or history of myocardial infarction, unstable angina or acute coronary syndrome within 6 months of screening.

• Malabsorption, disease significantly affecting gastrointestinal function, or resection of the stomach or small bowel, ulcerative colitis, symptomatic inflammatory bowel disease, or partial or complete bowel obstruction.

• Known history of Human Immunodeficiency Virus (HIV), active infection with Hepatitis B Virus (HBV), and/or Hepatitis C Virus (HCV). Subjects who are positive for hepatitis B core antibody or hepatitis B surface antigen must have a negative polymerase chain reaction (PCR) result before enrollment. Those who are PCR positive will be excluded.

• Lactating or pregnant women.

• Inability to swallow capsules.

• History of non-compliance to medical regimens.

• Unwilling or unable to comply with the protocol.

• Major surgery within 4 weeks of first dose of study drug.

• No active infections requiring systemic therapy.

• Known bleeding disorders with the exception of acquired Von Willebrand Disorder suspected on the basis of WM.

• History of stroke or intracranial hemorrhage within 6 months prior to enrollment.

Related Conditions & MeSH terms

• Waldenstrom Macroglobulinemia
• Waldenstrom's Macroglobulinemia

Intervention

Drug:
• Ibrutinib

Locations

Country	Name	City	State
United States	Dana-Farber Cancer Institute	Boston	Massachusetts
United States	Massacusetts General Hospital	Boston	Massachusetts

Sponsors (2)

Lead Sponsor	Collaborator
Dana-Farber Cancer Institute	Pharmacyclics LLC.

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Other	Time to Response	The amount of time between starting treatment and attaining at least a minor response to therapy	4 years
Other	Progression Free Survival	The number of participants who have not experienced disease progression 6 years after therapy initiation	6 years
Other	Overall Survival	The number of participants who are still living 6 years after initiation of ibrutinib	6 years
Primary	Major Response Rate	To asses the percentage of participants with a Partial Response (PR) (50% reduction or more in serum IgM) or better.	4 years
Primary	Best Overall Response Rate	To asses the percentage of participants with an Minor Response (MR) (25% reduction or more in serum IgM) or better.	4 years
Secondary	Duration of Response	The amount of time between attainment of at least a minor response and disease progression.	6 years